NCT04923347View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4CompletedINTERVENTIONAL
Enrollment

229

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

FF/UMEC/VI

FF/UMEC/VI will be administered

DEVICE

ELLIPTA

Participants will receive FF/UMEC/VI using ELLIPTA inhaler.

Trial Locations (14)

44009

GSK Investigational Site, Nagpur

57001

GSK Investigational Site, Mysore

302039

GSK Investigational Site, Jaipur

305001

GSK Investigational Site, Ajmer

334001

GSK Investigational Site, Bikaner

401107

GSK Investigational Site, Mumbai

411047

GSK Investigational Site, Pune

422007

GSK Investigational Site, Nashik

500084

GSK Investigational Site, Hyderabad

560092

GSK Investigational Site, Bangalore

605402

GSK Investigational Site, Pondy-Cuddalore ECR Main Road Pillaiyarkuppam Pond

673008

GSK Investigational Site, Kozhikode

700014

GSK Investigational Site, Kolkata

700027

GSK Investigational Site, Kolkata

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04923347 - A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter